

## **Product datasheet for TL302335**

## PDP1 Human shRNA Plasmid Kit (Locus ID 54704)

## **Product data:**

**Product Type:** shRNA Plasmids

Product Name: PDP1 Human shRNA Plasmid Kit (Locus ID 54704)

**Locus ID:** 54704

**Synonyms:** PDH; PDP; PDPC; PPM2C

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** PDP1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 54704).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001161778, NM 001161779, NM 001161780, NM 001161781, NM 018444, NM 018444.1,

NM 018444.2, NM 018444.3, NM 001161779.1, NM 001161780.1, NM 001161778.1,

NM 001161781.1, BC047619, BC047619.1, BC064978, BC098343, BM973633,

NM 001161781.2, NM 018444.4, NM 001161780.2

UniProt ID: Q9P0|1

**Summary:** Pyruvate dehydrogenase (E1) is one of the three components (E1, E2, and E3) of the large

pyruvate dehydrogenase complex. Pyruvate dehydrogenase kinases catalyze phosphorylation of serine residues of E1 to inactivate the E1 component and inhibit the complex. Pyruvate dehydrogenase phosphatases catalyze the dephosphorylation and activation of the E1

component to reverse the effects of pyruvate dehydrogenase kinases. Pyruvate

dehydrogenase phosphatase is a heterodimer consisting of catalytic and regulatory subunits. Two catalytic subunits have been reported; one is predominantly expressed in skeletal muscle and another one is is much more abundant in the liver. The catalytic subunit, encoded by this gene, is the former, and belongs to the protein phosphatase 2C (PP2C) superfamily. Along with the pyruvate dehydrogenase complex and pyruvate dehydrogenase kinases, this enzyme is located in the mitochondrial matrix. Mutation in this gene causes pyruvate dehydrogenase phosphatase deficiency. Multiple alternatively spliced transcript variants encoding different

isoforms have been identified.[provided by RefSeq, Jun 2009]



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com





shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a>. If you need a special design or shRNA sequence, please utilize our <a href="mailto:custom shRNA service">custom shRNA service</a>.

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).